Fluidigm to Participate in Upcoming Health Care Investor Conferences
August 20, 2019 16:05 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
CORRECTING and REPLACING - Fluidigm Announces Second Quarter 2019 Financial Results
August 02, 2019 00:41 ET
|
Fluidigm Corporation
Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal Markers and Imaging Mass...
Fluidigm Announces Second Quarter 2019 Financial Results
August 01, 2019 16:05 ET
|
Fluidigm Corporation
Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal Markers and Imaging Mass...
Fluidigm Highlights New Advancements in Deep Cellular Profiling from Circulation to Tissue at CYTO 2019
June 20, 2019 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., June 20, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Fluidigm Introduces the First Complete Sample-to-Answer Solution for Deep Immune Profiling by Mass Cytometry
March 28, 2019 08:30 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., March 28, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
Foundational 10,000 Immunomes Project Uses Mass Cytometry to Establish a Reference Standard for the Human Immune System
October 25, 2018 08:30 ET
|
Fluidigm Corporation
Providing the largest source of standardized, multi-omic immune data from healthy human subjects to accelerate translational research SOUTH SAN FRANCISCO, Calif., Oct. 25, 2018 (GLOBE NEWSWIRE) --...